whereas over the last years fierce generic competition regarding the first line Antiretroviral Drugs (ARVs) has contributed to a price reduction of almost # %, from USD # to approximately USD # per patient per year, but the prices for the second line drugs, which patients need, as resistance develops naturally, remain high, mostly due to increased patent barriers in the key countries producing generic medicines
Ναι αλλά δεν θα το κάνεις αν θέλεις τα διαμάντιαoj4 oj4